Clinical Trial

Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-17.
Status change: Not Yet Recruiting → Recruiting 2025-08-30
Trial Details
NCT Number NCT06425120
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions Coronary Heart Disease
Enrollment 240 participants
Start Date 2024-06-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08